- Home
- LNTH vs ROIV Comparison
LNTH vs ROIV Comparison
Compare LNTH & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LNTH | ROIV |
|---|---|---|
| Founded | 1956 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 28.7B |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LNTH | ROIV |
|---|---|---|
| Price | $99.65 | $35.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | ★ $107.74 | $48.08 |
| AVG Volume (30 Days) | 805.3K | ★ 6.9M |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.91 | N/A |
| Revenue | ★ $343,374,000.00 | $8,260,000.00 |
| Revenue This Year | N/A | $530.75 |
| Revenue Next Year | $10.29 | $685.92 |
| P/E Ratio | $34.19 | ★ N/A |
| Revenue Growth | ★ 3.62 | N/A |
| 52 Week Low | $49.67 | $15.25 |
| 52 Week High | $111.86 | $42.50 |
Technical Indicators
Market Signals| Indicator | LNTH | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 38.96 | 46.25 |
| Support Level | $98.81 | $33.15 |
| Resistance Level | $101.24 | $37.59 |
| Average True Range (ATR) | 0.40 | 1.21 |
| MACD | -0.04 | -0.40 |
| Stochastic Oscillator | 18.97 | 22.31 |
Price Performance
Historical ComparisonAbout LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.